Q1
– Completion of Phase 1/2a Part I dose escalation. Initiate Part II to evaluate repeated treatments.
Q1
– $40M Series B funding
2018.03.02
Q1
– Completion of Phase 1/2a Part I dose escalation. Initiate Part II to evaluate repeated treatments.
Q1
– $40M Series B funding
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© Rakuten Medical Inc. 2022, All rights reserved.